Juvenescence Partner AgeX Therapeutics Announces Preprint Article Relating to Regeneration, Aging, and Cancer March 12, 2021 AgeX Therapeutics announced the online publication of data relating to regeneration, aging, and cancer in bioRxiv.
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement March 02, 2021 AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease December 30, 2020 LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy...
Juvenescence Partner AgeX Therapeutics Sublicenses Stem Cell Line for Development of Covid-19 Therapy October 28, 2020 AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes....
Juvenescence Announces Licensing Agreement with Evgen Pharma PLC September 15, 2020 Juvenescence announces a partnership with Evgen Pharma PLC to license its sulforaphane Sulforadex® stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
Relation Therapeutics Receives $1.3M Grant From the Gates Foundation to Identify Covid-19 Therapeutic Candidates September 01, 2020 Relation Therapeutics, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.
LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology August 27, 2020 LyGenesis, a clinical-stage biotechnology company announced today the publication of a new peer-reviewed paper published in journal Hepatology on its organ regeneration technology.
G3 Therapeutics and Juvenescence form Juvenomics June 01, 2020 Juvenescence Limited and G3 Therapeutics announced the formation of Juvenomics Limited, a joint venture between the two parent companies.
AgeX Therapeutics and Sernova collaborate to engineer Universal Locally Immune Protected Cell Therapies May 29, 2020 AgeX, a Juvenescence partner, and Sernova collaborate to utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for the treatment of type I diabetes and hemophilia A.
AgeX Therapeutics licensee ImStem Biotechnology announces FDA Cleared Investigational New Drug Application March 20, 2020 AgeX Therapeutics, a Juvenescence partner, announced that ImStem Biotechnology has received notification from the FDA that it has cleared the investigational New Drug application to evaluate IMS001 for the treatment...
AgeX Therapeutics to collaborate with University of California, Irvine on Neural Stem Cell Research Program February 03, 2020 Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform. Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions. Builds on...
AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells January 29, 2020 AgeX, a Juvenescence partner, announced a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.
